Every material Form 8-K Nuvation Bio Inc. has filed with the SEC since July 06, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Nuvation Bio reported third quarter 2026 total revenue of $45.0 million, up from $13.1 million a year earlier, driven by $27.5 million in net product revenue from IBTROZI. The net loss narrowed to $41.9 million, or $(0.12) per share, from $55.8 million, or $(0.16) per share, a year earlier, while cash, cash equivalents and marketable securities were $663.4 million as of September 30, 2026. The filing gives no revenue or earnings guidance for future periods.
Total revenue was $45.0 million for the quarter, versus $13.1 million in the third quarter of 2025.
Net product revenue from IBTROZI was $27.5 million, an 18% quarter-over-quarter increase.
Net loss was $41.9 million, or $(0.12) per share, compared with $55.8 million, or $(0.16) per share, a year earlier.
Research and development expenses rose to $32.7 million from $28.8 million, and SG&A expenses rose to $42.6 million from $37.4 million.
Nuvation Bio reported second quarter 2026 results, with total revenue of $31.7 million, up from $4.8 million a year earlier, driven by $23.2 million in net product revenue from IBTROZI. The net loss widened to $62.8 million, or $(0.18) per share, from $59.0 million, or $(0.17) per share, a year earlier, so shareholders face higher losses even as revenue grew.
Total revenue was $31.7 million for the quarter ended June 30, 2026, versus $4.8 million a year earlier; net product revenue from IBTROZI was $23.2 million.
Net loss was $62.8 million, or $(0.18) per share, compared with $59.0 million, or $(0.17) per share, in the second quarter of 2025.
Cash, cash equivalents, and marketable securities were $661.0 million as of June 30, 2026, before $36.5 million in net overallotment proceeds received in July 2026.
The company completed a public offering of 0.75% Convertible Senior Notes in July 2026 with estimated net proceeds of approximately $279.1 million.
Nuvation Bio issued an additional $37.5 million of 0.75% convertible senior notes due 2032 on July 6, 2026, after underwriters fully exercised their option, bringing the total offering to $287.5 million. The company estimates net proceeds of about $277.6 million and plans to use the remaining proceeds for general corporate purposes after paying about $2.2 million for additional capped call transactions.
Additional notes of $37.5 million issued July 6, 2026; total offering $287.5 million
Estimated net proceeds of approximately $277.6 million, inclusive of the additional notes
Notes bear 0.75% annual interest, mature July 1, 2032, and are general unsecured obligations
Capped call cap price of $10.4580 per share, a premium of 80.0% over the June 25, 2026 closing price on the NYSE
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Nuvation Bio Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →